Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Sarpogrelate Dose-Response in Cerebral Infarction
NCT00147303Phase 3Completed
- Sponsor
- Mitsubishi Tanabe Pharma Corporation
- Start
- Apr 2004
- Primary completion
- Jan 2005
- Modality
- Small Molecules
01
Overview
A Phase 3 trial of sarpogrelate in cerebral infarction, sponsored by Mitsubishi Tanabe Pharma Corporation. Started Apr 2004; status: completed.
02
Drugs
sarpogrelate
03
Conditions
cerebral infarction
Beyond the preview
Go deeper on NCT00147303.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00147303.